Open-house pharmaceutical discount agreements for Sorafenib, ATC L01EX02

Summary

This is an open-house model for non-exclusive pharmaceutical discount agreements covering Sorafenib, ATC L01EX02. AOK Bayern intends to offer identical, non-negotiable agreements to all interested pharmaceutical companies that meet the stated eligibility conditions; there is no competitive selection among applicants. The earliest contract start date is 1 November 2026, contracts end on 31 October 2028, and participation is possible until 3 September 2028. Applicants must submit the signed contract, the signed list of covered medicines and a signed reliability declaration. Complete documents may be submitted on paper with handwritten signatures or electronically with a qualified electronic signature. The exact requirements must be checked in the official tender documents.